Atlas Venture Fund XI, L.P.'s Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Oct 26, 2021
- Accession no.
- 0001104659-21-130026
- Filed
- Oct 26, 2021, 5:01 PM ET
- Trade date
- Oct 26, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $3.00M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionAcquired | +1,372,998 | –F1 | – | 1,399,313 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +624,089 | –F3 | – | 2,023,402 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionAcquired | +548,442 | –F4 | – | 548,442 | Indirect | |
| Oct 26, 2021 | Common Stock | PPurchaseAcquired | +187,500 | $16.00 | +$3,000,000 | 735,942 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 26, 2021 | Common Stock | CConversionDisposed | −1,372,998 | –F1 | – | 0 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −624,089 | –F3 | – | 0 | Indirect | |
| Oct 26, 2021 | Common Stock | CConversionDisposed | −548,442 | –F4 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F3
The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F4
The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.